Epoxomicin, a new antitumor agent of microbial origin
- J Antibiot (Tokyo). 1992 Nov;45(11):1746-52. doi: 10.7164/antibiotics.45.1746.
- 1. Bristol-Myers Squibb Research Institute, Tokyo, Japan.
An actinomycete strain No. Q996-17 produced a novel compound, epoxomicin, which exhibited in vivo antitumor activity against B16 Melanoma. Structural studies indicated that it is a new member of the epoxy-beta-aminoketone group, and is closely related to eponemycin.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
Research Areas: Inflammation/Immunology
-